Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $58,156.65 in Stock

Blueprint Medicines Co. (NASDAQ:BPMCGet Free Report) insider Christopher K. Murray sold 621 shares of Blueprint Medicines stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $93.65, for a total value of $58,156.65. Following the completion of the transaction, the insider now owns 36,374 shares of the company’s stock, valued at approximately $3,406,425.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Blueprint Medicines Price Performance

NASDAQ BPMC opened at $92.30 on Friday. The company has a fifty day moving average of $84.83 and a 200 day moving average of $69.06. Blueprint Medicines Co. has a 1 year low of $40.48 and a 1 year high of $101.00. The company has a debt-to-equity ratio of 1.60, a quick ratio of 3.66 and a current ratio of 3.76.

Blueprint Medicines (NASDAQ:BPMCGet Free Report) last posted its earnings results on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.04) by $0.22. The company had revenue of $71.96 million during the quarter, compared to the consensus estimate of $67.34 million. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The firm’s quarterly revenue was up 85.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.65) earnings per share. On average, research analysts anticipate that Blueprint Medicines Co. will post -5.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of BPMC. Raymond James & Associates raised its position in shares of Blueprint Medicines by 18.6% in the first quarter. Raymond James & Associates now owns 31,565 shares of the biotechnology company’s stock worth $2,016,000 after acquiring an additional 4,945 shares during the period. US Bancorp DE raised its position in shares of Blueprint Medicines by 11.4% during the 1st quarter. US Bancorp DE now owns 7,234 shares of the biotechnology company’s stock worth $463,000 after purchasing an additional 743 shares during the last quarter. MetLife Investment Management LLC raised its position in shares of Blueprint Medicines by 53.9% during the 1st quarter. MetLife Investment Management LLC now owns 31,782 shares of the biotechnology company’s stock worth $2,030,000 after purchasing an additional 11,131 shares during the last quarter. Rhumbline Advisers raised its position in shares of Blueprint Medicines by 1.5% during the 1st quarter. Rhumbline Advisers now owns 63,434 shares of the biotechnology company’s stock worth $4,052,000 after purchasing an additional 924 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of Blueprint Medicines by 0.9% during the 1st quarter. BlackRock Inc. now owns 5,383,138 shares of the biotechnology company’s stock worth $343,876,000 after purchasing an additional 46,264 shares during the last quarter.

Analyst Ratings Changes

Several analysts have issued reports on BPMC shares. Wells Fargo & Company raised their price objective on shares of Blueprint Medicines from $86.00 to $115.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 19th. Wedbush reissued an “outperform” rating and issued a $97.00 price objective on shares of Blueprint Medicines in a research note on Monday, February 5th. Raymond James raised their price objective on shares of Blueprint Medicines from $85.00 to $100.00 and gave the stock a “strong-buy” rating in a research note on Friday, December 22nd. JMP Securities reaffirmed a “market outperform” rating and set a $114.00 price target on shares of Blueprint Medicines in a research note on Friday, February 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $85.00 price target on shares of Blueprint Medicines in a research note on Monday, December 11th. Four analysts have rated the stock with a sell rating, two have given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Blueprint Medicines has an average rating of “Hold” and an average price target of $85.43.

Get Our Latest Report on Blueprint Medicines

About Blueprint Medicines

(Get Free Report)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.

See Also

Insider Buying and Selling by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.